Quick Facts: НУКАЛА (Mepolizumab) Approved Uses

• Severe Eosinophilic Asthma (SEA): May help manage this condition in patients aged six years and older.
• Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): May assist in the management of this condition in adults.
• Eosinophilic Granulomatosis with Polyangiitis (EGPA): Indicated for the management of this specific type of vasculitis in adults.
• Hypereosinophilic Syndrome (HES): May help manage this condition in patients aged 12 years and older.
• Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): Indicated for add-on maintenance treatment in adults with inadequately controlled disease.

---

НУКАЛА is approved for use as an add-on maintenance treatment in patients with certain inflammatory conditions that involve elevated levels of eosinophils. This medication is intended to be used in conjunction with other established therapies to support the overall treatment regimen, not as a standalone treatment or for acute symptoms.

In the context of Severe Eosinophilic Asthma (SEA) in patients aged six and older, treatment may lead to a reduction in the rate of severe exacerbations. For Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in adults, it is an option when response to standard intranasal corticosteroids is inadequate, and it may assist in the management of nasal polyp size and related symptoms.

It is also indicated for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in adults and Hypereosinophilic Syndrome (HES) in patients aged 12 and older, conditions characterized by persistently high eosinophil counts. Additionally, it is an option for adults with inadequately controlled Eosinophilic Chronic Obstructive Pulmonary Disease (COPD).

Eligibility Map: Who Can and Cannot Use NUCALA — Official Regulatory Information

NUCALA (mepolizumab) use is governed by strict regulatory rules regarding age, pre-existing conditions, and specific physiological states, as defined by government health authorities.

Scope	Regulatory Status (as stated in label)
Populations for whom use is allowed:	Patients ge6 years old for Severe Eosinophilic Asthma (SEA); ge12 years for Hypereosinophilic Syndrome (HES); Adults ge18 years for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Eosinophilic Granulomatosis with Polyangiitis (EGPA), and Chronic Obstructive Pulmonary Disease (COPD).
Populations for whom use is contraindicated:	Patients with a known history of hypersensitivity to mepolizumab or any of the inactive ingredients.
Eligibility-related restrictions:	Not for use in treating acute breathing problems, such as acute bronchospasm or status asthmaticus. Patients with a pre-existing parasitic (helminth) infection must be treated for that infection before starting NUCALA therapy. Corticosteroids must not be stopped abruptly upon beginning treatment.
Comorbidity-specific rules:	No dose adjustment is required for patients with renal impairment or hepatic impairment.
Pregnancy and lactation status:	Use during pregnancy should only be considered if the expected benefit justifies the potential risk to the fetus due to limited data. For lactation, a decision must be made whether to discontinue breastfeeding or discontinue the drug due to unknown excretion into human milk.

---

Official regulatory documents define the eligible patient population by setting strict minimum ages that vary by condition and by listing absolute prohibitions, ensuring the medicine is used only for its intended long-term maintenance purpose.

Interactions with other medicines and products — Official Regulatory Information for Mepolizumab ( НУКАЛА)

The interaction profile for Mepolizumab, a humanized monoclonal antibody, is primarily characterized by the absence of documented pharmacokinetic interference with commonly used small-molecule drugs. Official regulatory documents focus instead on specific co-therapy management rules.

Category	Official Regulatory Finding
PK/Metabolic Interactions	None documented. Mepolizumab is degraded by proteolytic enzymes, not by hepatic CYP450 enzymes. Population pharmacokinetic analysis found no evidence of an effect of commonly co-administered small-molecule drugs on Mepolizumab exposure.
Contraindicated Combinations	Hypersensitivity to the active substance or excipients is the only formal contraindication listed in relation to the medicine's use.

---

Official Interaction Statements and Restrictions

• Corticosteroid Co-therapy: Systemic or inhaled corticosteroids must not be abruptly discontinued upon initiation of Mepolizumab therapy. This constitutes a mandatory co-therapy management rule, and any dose reduction must be gradual and supervised.
• Timing-Based Restriction: Treatment must be discontinued if a patient with a parasitic (helminth) infection fails to respond to anti-helminth treatment, which is a specific timing-based substance restriction.
• Food and Supplements: Regulatory labeling reports no known interaction restrictions with food, alcohol, or herbal products.
• Population Notes: Elimination is unlikely to be affected in patients with hepatic or renal impairment due to the drug's non-CYP and non-renal clearance mechanism.

The official regulatory profile is defined by specific procedural constraints for co-treatment and the clear absence of typical metabolic drug-drug interactions, confirming its specialized interaction structure.

Targeted Neutralization of Interleukin-5 (IL-5)

The mechanism of action begins with the specific binding of Mepolizumab to the circulating Interleukin-5 (IL-5) protein. By forming an inert complex, the drug functions as a neutralizing antagonist, preventing IL-5 from activating its corresponding receptor on immune cells. This early molecular step is central to influencing the Th2 immune pathway.

---

Interruption of Eosinophil Survival and Production

The functional blockade of IL-5 disrupts the critical signal necessary for eosinophil homeostasis. The absence of IL-5 stimulation accelerates the apoptosis (programmed cell death) of existing eosinophils and suppresses the maturation and release of new cells from the bone marrow. The resulting physiological consequence is a targeted reduction of eosinophil concentration in the bloodstream and tissues, which reduces the presence of eosinophils available to release inflammatory and cytotoxic granule proteins.

---

Pathway-Specific Physiological Influence

The mechanism's functional relevance is entirely constrained to processes where the IL-5/eosinophil axis is the dominant driver. This targeted action provides a highly focused functional change in the specific inflammatory response linked to eosinophils, without exerting effects on inflammation driven by other primary cellular pathways (e.g., neutrophils or mast cells).

Administration Overview

НУКАЛА is administered as an injection under the skin (subcutaneously). It is typically provided in forms suitable for use by healthcare professionals or for self-administration by patients and caregivers after appropriate training.

Administration Sites

When preparing for an injection, the following areas of the body are commonly used:

• Thighs: The front or outer area of the upper legs.
• Abdomen: The stomach area, avoiding the region immediately surrounding the belly button.
• Upper Arm: The outer area of the upper arm (this site is generally used when a caregiver or healthcare professional is administering the dose).

It is recommended to rotate the injection site with each dose to maintain skin health. Injections should not be given into areas where the skin is bruised, tender, red, or hard.

Preparation for Use

Before administration, the product is typically removed from refrigeration and allowed to reach room temperature. This process usually takes approximately 30 minutes. The medication should be inspected visually; the liquid should be clear to opalescent and colorless to pale yellow or pale brown. Small air bubbles are considered normal and do not require removal.

Training and Support

For individuals who will be administering the medication at home, a healthcare provider will demonstrate the correct technique. This includes instruction on how to prepare the site, how to use the specific delivery device (such as a pre-filled autoinjector or pre-filled syringe), and how to dispose of used materials safely. Patients and caregivers should only attempt administration once they feel confident in the process as taught by their healthcare professional.

Research evidence / Overview of Studies for NUCALA (Mepolizumab)

Evidence for Use in Severe Eosinophilic Asthma

The primary research involved several major, controlled clinical trials, known as Randomized Controlled Trials (RCTs). These studies primarily focused on adults and adolescents with a specific type of severe asthma linked to elevated levels of eosinophils, who were already using standard inhaled and oral corticosteroid therapies. Researchers aimed to measure how frequently patients experienced acute or disruptive asthma episodes (exacerbations) and researched the change in the dose of maintenance oral corticosteroids (OCS) used by patients over short- to intermediate-term observation periods.

Trials reported data regarding the frequency of exacerbation events, where differences were recorded between the mepolizumab group and the placebo group over the study duration. Trials focused on OCS reduction reported observations regarding how some patients changed their daily OCS medication dosage while continuing to meet study criteria for asthma control. Researchers monitored and tracked changes in physiological measures, such as lung function.

Evidence for Use in Chronic Rhinosinusitis with Nasal Polyps

Research examining the use of NUCALA for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) was based on a primary, one-year, placebo-controlled RCT. This study included adults with conditions characterized by functional limitations due to severe, recurrent nasal polyps that had not responded well to standard intranasal corticosteroid treatment. Researchers focused on objectively measuring outcomes such as the change in size of nasal polyps and patient-reported outcomes describing perceived discomfort, such as nasal obstruction and overall symptom severity.

The controlled trial reported measurements describing changes in the objective Nasal Polyp Score (NPS) over the 52-week period, with recorded differences between the study groups. Similar patterns were described in patient-reported measures of nasal blockage and obstruction. Researchers also monitored and tracked the frequency of surgical intervention and the use of systemic corticosteroids across the observed patient populations.

Evidence for Use in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

The evidence base for NUCALA in Eosinophilic Granulomatosis with Polyangiitis (EGPA) includes a key 52-week, placebo-controlled RCT. This research was evaluated in adults with EGPA, a condition involving periods of heightened symptoms, who were being managed with stable doses of systemic corticosteroids. Studies monitored and measured outcomes related to sustained remission (defined by disease activity scores and stable corticosteroid use) and changes in the overall cumulative systemic glucocorticoid dose required by patients over the study period.

The core trial reported measurements regarding the achievement of sustained remission over the year-long period, with observed differences between the study groups. Researchers tracked the amount of cumulative systemic glucocorticoid dose used by each patient during the study, and differences in total amounts were recorded between the study groups. The rate of disease flare was also monitored and documented. Due to the rarity of EGPA, the main trial utilized a small sample size.

Evidence for Use in Hypereosinophilic Syndrome (HES)

Research explored the use of NUCALA in Hypereosinophilic Syndrome (HES) through a central 32-week, placebo-controlled RCT. The research included adults and adolescents aged 12 years and older with this rare condition, which is characterized by fluctuating or episodic manifestations. Researchers focused on measuring the proportion of patients who experienced an HES flare (an acute or disruptive episode requiring treatment escalation) and the ability of patients to change their existing HES therapies, such as oral corticosteroids.

The controlled trial reported patterns regarding the percentage of patients who experienced an HES flare over the 32-week period, with differences in the frequency of such events recorded between the study groups. The trial also tracked and reported the percentage of patients who successfully changed or discontinued their concurrent HES therapy.

Evidence for Use in Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)

Research has explored the use of NUCALA in a specific sub-group of adult patients with COPD who exhibit high blood eosinophil counts. Multiple large-scale RCTs were applied in studies examining patient-reported experiences and outcomes describing episodic changes over observation periods lasting up to two years. The main outcome monitored was the annualized rate of moderate or severe COPD exacerbations.

Trials reported measurements regarding the annualized rate of moderate or severe COPD exacerbations, with differences observed between the mepolizumab group and the placebo group when stratified by specific high eosinophil count thresholds. Research highlights changes measured during the study period, but findings related to patient-reported outcomes describing perceived discomfort or changes in daily functioning were reported as mixed across some studies.

Long-Term Studies and Follow-up

The initial core regulatory trials for most indications had follow-up durations that were limited to less than one year. Consequently, much of what is understood about long-term use and the durability of the observed patterns comes from subsequent open-label extension studies. These extension studies track outcomes for several years and help to contextualize how patients reported their experience during extended periods of use. However, because these extension studies do not include a placebo group, the evidence quality for long-term outcomes and sustained response certainty remains low compared to the initial controlled trials.

What is Still Uncertain About NUCALA

Research has provided insight into short-term changes in symptoms and disease activity, but several research limitations are important to note. For most indications, the follow-up durations were limited in the core controlled trials, meaning the long-term effects on disease progression are not well characterized. Similarly, sample sizes were modest for the rare diseases studied (EGPA and HES).

Furthermore, the results apply only to the populations studied, who were specifically selected based on disease severity and, critically, their elevated eosinophil levels. Data for certain groups remain insufficient, such as children under the age of 12 for most indications, and evidence quality varies across studies when examining patient-reported outcomes in COPD. Research is ongoing to better understand the full range of long-term outcomes and the mechanisms behind why certain patients may or may not respond to the medicine.

Key Studies & References

1. A Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) (NCT02836496)

Common questions about НУКАЛА (FAQ)

Q: How does mepolizumab, the active ingredient in НУКАЛА, relate to a type of white blood cell called eosinophils?

A: Mepolizumab is a monoclonal antibody that targets a protein called interleukin-5 (IL-5). IL-5 is one of the key signals that helps regulate the production and survival of eosinophils.

Q: What is the goal of add-on treatment with НУКАЛА for severe eosinophilic asthma?

A: НУКАЛА is used as an add-on maintenance treatment for severe eosinophilic asthma. Clinical studies have shown that adding this medication to standard care for patients who have this type of asthma may lead to a reduction in the rate of asthma exacerbations (flare-ups) over time. This effect is thought to be due to a reduction in the number of eosinophils in the blood and airways.

Q: What information is available from clinical trials regarding НУКАЛА's use for severe eosinophilic asthma?

A: Trials involving adults and adolescents with severe eosinophilic asthma have demonstrated an association between the use of mepolizumab and a statistically significant reduction in the frequency of clinically significant asthma exacerbations compared to placebo, when both were used alongside standard therapy. Furthermore, some patients had an observed reduction in their required daily oral corticosteroid dosage while maintaining asthma control, but this should be assessed by a healthcare provider on a case-by-case basis.

Q: How is the effect of НУКАЛА typically monitored in patients who take it?

A: Since mepolizumab works to reduce the level of eosinophils, a healthcare provider will typically monitor a patient's blood eosinophil count over the course of treatment. Changes in the frequency of asthma exacerbations and the severity of symptoms are also key measures used to evaluate the patient’s response to the add-on therapy.

Q: Can НУКАЛА be used as a treatment for acute asthma attacks or status asthmaticus?

A: No, mepolizumab is not a rescue medication. It is indicated for maintenance treatment only. It should not be used for the rapid relief of acute asthma symptoms, sudden worsening of asthma, or status asthmaticus. Patients must continue to use their short-acting rescue inhalers for acute symptoms as prescribed by their doctor.

Storage and Disposal Requirements for NUCALA (Mepolizumab)

NUCALA must be stored according to strict regulatory guidelines to maintain its stability and effectiveness. The product must be kept in the refrigerator between 2 C and 8 C (36 F and 46 F) and must not be frozen.

Storage Conditions

Condition	Requirement
Temperature	2 C to 8 C (Do not freeze)
Protection	Store in the original carton to protect from light.
Stability Limit	May be stored out of the refrigerator (up to 30 C) for a maximum of 7 days total.

All medicines, including NUCALA, must be stored out of the sight and reach of children. Used pre-filled syringes and autoinjectors must be immediately disposed of in an FDA-cleared sharps disposal container. Unused or expired medication must be discarded in accordance with local pharmaceutical waste regulations.